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a  b  s  t  r  a  c  t
Peritoneal dissemination is a common consequence of a relapse following a radical surgical
treatment of gastric cancer. The development of the disease in the peritoneum depends
not  only on its stage, but also on free cancer cells exfoliated from the tumor mass or from
involved lymph nodes, and which are capable of being implanted in the peritoneum. Accord-
ing  to the latest TNM (7 edition; 2010) classification, patients with free cancer cells in the
peritoneal washings qualify for stage IV of the disease. Patients in whom free cancer cells
were found during the operation – have a recurrence of gastric cancer – mainly in the peri-
toneum, and the majority of them die within two years of the diagnosis. To properly assess
the prognosis, it is vital to determine the stage of cancer by additionally assessing the wash-
ings for the presence of free cancer cells before taking a therapeutic decision. This also
allows identifying those patients who require different medical procedures to obtain the
best  treatment results possible. Medical literature describes various methods of examin-
ing  peritoneal washings aimed at detecting free cancer cells. The methods apply differentcancer cell detection rates, sensitivity and specificity in prediction of a peritoneal relapse.
Oncological Departments performing the evaluation of the washings employ non-standard
methods of treatment in this group of patients and the results presented are promising.
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sical cytology employed for identification of free cancer cells
in the peritoneum, they used monoclonal antibodies directed
against the antigens on the surface of the cancer cells. He
Table 1 – Rate of cancer cells detection in the peritoneum









535  4.4% 23%
La Torre 2010 64 11% Data not
available
Bando 1999 1297 7.3% 49%
Kodera 1999 91 11% 40%
Bentrem 2005 371 6.5% Data not
available
Ribeiro 2006 220 6.8% Data not
available
Suzuki 1999 347 8.4% Data notreports of practical oncology and 
.  Introduction
he aim of the assessment of peritoneal washings in patients
reated for gastric cancer is to identify patients with free can-
er cells in the peritoneal cavity. The positive result of the
xamination applies to 4–11% of the patients in whom no
eritoneal dissemination of the disease is visible during the
iagnostic report. The presence of free cancer cells in the
eritoneal cavity is a negative factor as far as the prognosis
s concerned, as it is connected with a short survival status
12–15 months) and a quick relapse of the disease is reported
n all the patients.1–3
The result of peritoneal cytology was included in the 7th
dition of the TNM by the International Union Against Can-
er (UICC) and according to its directives the patients with a
ositive result are classified as M1  category, that is grade IV of
dvanced disease.4 According to the current TNM directives,
o properly determine the stage of gastric cancer, endoscopic
nd imaging examinations should be supplemented with the
esult of a diagnostic laparoscopy along with a lavage of the
eritoneum for free cancer cells.5–7
The European Society For Medical Oncology (ESMO) recog-
izes the examination of the peritoneal washings as an option
n preoperational diagnosis,8 while the American Society of
merican Gastrointestinal and Endoscopic Surgeons (SAGES)
ecommends carrying out peritoneal cytology during laparo-
copic diagnosis in patients with T3/T4 tumor if no peritoneal
issemination is found in their imaging diagnosis.9 Similarly,
he NNCN (National Comprehensive Cancer Network) direc-
ives also recommend laparoscopic diagnosis combined with
he examination of peritoneal washing before surgical treat-
ent in advanced T3/T4, N+ patients, and in all patients
ho  receive perioperative chemotherapy as the first line of
reatment.10 Yet, despite the fact that we have knowledge on
he significance of the presence of free cancer cells in the
eritoneum, currently there is no gold standard treatment for
he patients.11 There appeared articles in medical literature,
hich take into account therapeutic strategies aimed at con-
ersing the cytological status in the peritoneum. The results
escribed are promising–they affect the lengthening of sur-
ival time of the examined patients which can in the future
mprove the results of the treatment of patients with stomach
ancer at this level of advancement.12–14
.  Pathomechanism  of  peritoneal
issemination  and  diagnostic  methods  of  free
ancer  cells  in  the  peritoneum
he presence of free cancer cells is the result of the spon-
aneous exfoliation of cancer cells from the main tumor
r from the metastatic lymph nodes.15 It can also be the
esult of a perioperative trauma (tumor manipulation, intra-
perative perforation, severing the lymphatic vessels, blood
essels, lymphadenectomy).16 While circulating in the per-
toneal fluid, the cells become implanted on the surface of
he peritoneum with the participation of adhesive molecules
nd then they penetrate the sub-peritoneal layer where they
urther divide.17–19 Another mechanism of cell implantationtherapy 2 2 ( 2 0 1 7 ) 434–440 435
is connected to the so-called lymph channels (stomata) on
the peritoneum – responsible for the elimination of all the
exfoliated cell elements from the peritoneal cavity (including
the cancer cells), which, due to their size, are not absorbed
by the blood-peritoneum barrier.20 So far, in the diagnos-
tics of free cancer cells in the peritoneum, medical literature
has accepted classical peritoneal cytology, the immunohisto-
chemical method with the use of antibodies against antigens
present in cancer cells. (Ber-Ep4, HEA 125, B72.3), the immune-
enzymatic method [(level CEA (carcinoembryonic antigen) in
peritoneal washings)] and the molecular method in which
the CEA level is examined with the use of RT-PCR (Reverse
Transcriptase-Polymerase Chain Reaction Technique).
Most publications concerning the examination of washings
from the peritoneal cavity are based on the classical cytologi-
cal analysis in which the cellular sediment obtained from the
spun peritoneal liquid is smeared on a glass side. It is then
examined under a microscope by an experienced patholo-
gist using the pigmentary method. The method is recognized
to be the gold standard method21 due to its high specificity
(Table 4), easiness, low cost and the relatively short analysis
time of 20–30 min. Using this method, the detection rate of free
cancer cells in the peritoneum in patients subjected to poten-
tially radical surgery treatment is 4–11%. If one considers only
the cases where the serous membrane is infiltrated, then the
rate rises to between 22% and 30%. If peritoneal dissemination
happens alongside as a concomitant, then the rate applies to
23–83% of the patients (Table 1).
Immunohistochemical methods are complementary to
classical cytological evaluation. They are characterized by
higher sensitivity but at the cost of specificity (Table 4). The
use of monoclonal antibodies (Ber Ep4, HEA 125, B72.3) allows
one to identify antigens appearing on the surface of the cancer
cells of the stomach in the peritoneum. In 1998 Benevolo and
co-workers22 published a study in which, in addition to clas-available
Burke 1998 76 4% 59%
Lee 2012 1072 10.3% 52%
Nath 2008 255 7.2% 83%
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Table 2 – Rate of cancer cells detection in the peritoneum
using the immunohistochemical method.
Author/year Presence of free
cancer cells –
classical cytology
Presence of free cancer
cells
Immunohistochemistry
Benevolo 1998 21% 35%
Rosenberg 2006 Not carried
out
21.4%
Table 4 – Sensitivity and specificity in anticipating
peritoneal relapse for particular diagnostic methods.
Diagnostic method Sensitivity (%) Specificity (%)
Cytology 11–80 86–100
Immunohistochemistry 23–100 81–93
CEA level 22–75 77–96Nekarda 1999 6% 20%
Vogel 1999 20% 30%
observed a 14% increase in the detection of cells in comparison
with the cytological method. In the group of patients iden-
tified exclusively with the use of the immunohistochemical
method, he observed similar recurrence rates of the disease
and long survival periods as in the group of patients with
positive cytology. Other tests in which immunohistochemi-
cal methods were used also showed higher detection rates
(Table 2).23–25
The other two diagnostic methods described in medical
literature with reference to stomach cancer cells in the per-
itoneal cavity are based on the identification of the cancerous
marker of the carcinoembryonic antigen (CEA) in peritoneal
washings. In the immune enzymatic method, the CEA level is
determined in the supernatant left following the spinning of
the sediment from the washing liquid, whereas in the molecu-
lar test, the RT-PCR technique is employed (Table 3). In his work
Wang and co-workers26 compared the conventional periton-
eal cytology with the marking of the CEA level in the peritoneal
washings using immunoenzymatic methods and RT-PCR. The
detection rates of cancer cells for the three methods were
15%, 20% and 27.5%, respectively. Kodera and co-workers27
indicate in their study that the difference between cytol-
ogy and RT-PCR CEA was 10% in favor of the latter method
(28% versus 18%).
3.  Presence  of  free  cancer  cells  in  the
peritoneal  cavity  and  risk  of  peritoneal
dissemination
Peritoneal dissemination in the cancerous process is the most
common cause of failure after radical surgery for gastric can-
cer. It affects about 60% of patients receiving surgery when
the tumor is at the advance T3/T4 level and the average sur-
vival period is 3 months.14,28,29 One of the factors for peritoneal
dissemination, apart from the degree of tumor invasion, the
involvement of lymph nodes by cancer, the degree of diversity,
Table 3 – Rate of cancer cells detection in the peritoneum
for CEA dependant methods (immunoenzymatic and
molecular).
Author/year RT-PCR Cyt + CEA – protein
Wang 2005 27.5% 15% 20%
Kodera 1998 28% 18% –
Katsuragi 2007 40% – –
Yamamoto 2007 – – 17.5%
Abe – – 17.9%
Ji-Kun Li 2005 – 23.4% 40.6%RT-PCR CEA 31–100 59–95
and the histological type according to the Lauren classification
– is the presence of free cancer cells in the peritoneum dur-
ing the surgery. Data from medical literature pertaining to the
sensitivity and specificity of particular diagnostic methods in
anticipating peritoneal relapse are shown in Table 4.3
The highest sensitivity of conventional cytology was
obtained by Kodera (80%) in a study published in 1999. In a
group of 10 patients who had a relapse of peritoneal dissemi-
nation, 8 had a positive cytology result of peritoneal washings.
In a group of 81 patients with a negative result, 2 patients had
peritoneal dissemination (specificity – 97.5%).30 In their study
Li and co-workers31 obtained a similar high sensitivity and
specificity of cytology in anticipating peritoneal relapse (73.7%
and 97.8%). It should however be noted that most available
medical literature presents a lower sensitivity of the method
– the result being a big percentage of patients with periton-
eal relapse of the disease with negative cytology result.3 The
restrictions of the method stem from the low sensitivity and
interpretational difficulties in the differentiation between well
diversified cancerous cells and benign mesothelium cells. Its
indubitable advantage is the specificity, which reaches almost
100%.32 At present, molecular tests based on the detection
mRNA  CEA have become the standard procedure at centers
performing the assessment of peritoneal washings. The pres-
ence of the marker in peritoneal washings is linked to the
depth of the invasion of the cancerous tumor, to the involve-
ment of lymph nodes by cancer and to the stage of the cancer.
In medical literature there are studies, which compare
various diagnostic methods used in anticipating peritoneal
relapse. In a publication of 200526 Wang and co-workers,
when comparing conventional cytology with dependent CEA
methods (immunoenzymatic and molecular), obtained 33.3%
cytology sensitivity at 93% of specificity. For comparison, the
sensitivity of the enzymatic and monocular methods in this
study was 67% and 50%, respectively, at specificity of 93%
and 89%. Similar results have been obtained by other authors
who published data comparing the two diagnostic methods –
Table 5.27,33,34
The comparative results obtained indicate that the molecu-
lar method, which uses CEA mRNA, boasts a higher sensitivity
than the classical cytology of peritoneal washings in anticipat-
ing peritoneal relapse.
Nevertheless, it is to be noted that in some studies the
rate of sensitivity26 and of specificity34 is low in the molec-
ular method. Falsely negative results of RT-PCR tests with
the use of mRNA  CEA are a result of a lack of expression of
the CEA marker in the cells of stomach cancer in peritoneal
washings. Falsely positive results, however, are linked to the
production of CEA by other cells of peritoneal fluid–leucocytes,
macrophages, endothelium cells, etc.27
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Table 5 – Comparison of sensitivity and specificity of the cytological and molecular method in anticipating peritoneal
relapse.
Author of test Number of
patients
Molecular method (RT = PCR CEA) Classical cytology
Sensitivity Specificity Sensitivity Specificity
Wang 2005 40 50% 89% 33% 93%
Kodera 1998 284 88% 81% 47% 96%
Tokuda 2003 136 93% 87.5% 31% 100%
Fuji 2002 49 100% 64% 33% 97%











Ribeiro/2005 Cytology 10.5 61 0.00001
Vogel/1999 Immunohistochemistry 25.7 40 0.007
Kodera/1999 Cytology 12.8 Data not available <0.0001





































Asian patients with a positive peritoneal fluid examina-
tion have a good alternative of receiving S1 chemotherapy.
Ako and co-workers39 evaluated the effect of S1 chemother-
apy (tegafur, gimeracyl, oteracil) administered as an adjuvant
Table 7 – Suggested therapeutic strategies for patients
with positive examination result of the peritoneal
washings.
Type of therapy Author/year
Surgical treatment with intensive lavage of
the peritoneum with physiological saline
Kuramoto/2009
Surgical treatment with intraperitoneal




Surgical treatment with S1 chemotherapy Ako/2008
Yonemura/2006Bentrem 2005 Cytology 14.8 
Lee/2011 Cytology 15.7 
Bonenkamp/1996 Cytology 13 
.  Prognostic  significance  of  the  results  of
eritoneal  washings  test
edical literature data clearly shows a difference in the sur-
ival of patients who  had free cancer cells in the peritoneum
s compared to the group of patients with negative peritoneal
ytology. The results are worse both in the case of patients who
eceived radical surgery (R0) and those who showed visible
ancer symptoms during laparotomy. Bando and co-workers35
nalyzed the cytology of fluid from the peritoneum in 1297
atients operated for gastric cancer. The result of the cytolog-
cal test of peritoneal washings was positive in 296 patients
24%). In this group only 2% of the patients lived up to 5 years
fter surgery, whereas in the case of negative result the rate
as 58% (p < 0.001). Patients with a positive result of periton-
al cytology included those who had radical surgery and those
hose surgery was restricted to exploratory laparotomy due
o the dissemination of the disease. In patients who under-
ent resection, one year and three-year survival rates were
7% and 0%, respectively. However, with peritoneal dissem-
nation present, one and three-year survival rates were 18%
nd 2% (p < 0.001). In patients with peritoneal dissemination
nd negative washing cytology result, one year and three-year
urvival rates were 43% and 9% (p < 0.001). A similar, negative
nfluence of the peritoneal fluid examination on survival with
 concurrent dissemination of the disease was also observed
y Fukigawa and co-workers.1
In a Dutch study36 535 patients who  received surgical
reatment for stomach cancer had their peritoneal washings
nalyzed and a positive result of the fluid examination was
btained in 4.4% of those who received radical treatment (R0).
owever, when peritoneal dissemination was found and when
he only treatment applied was palliative treatment, the rate
as 23%. Median survival for patients with a positive periton-
al cytology was 13 months; patients with a negative cytology
ived, on average, longer than 3 years (p < 0.001). No patient
ith a positive cytology result and who underwent palliative
reatment lived longer than a year.98.5 <0.0001
78 0.001
Data not available 0.0001
Table 6 contains data on the survival periods of patients
depending on the results of the examination of peritoneal
washings. Each of the authors who presented their findings
evidently confirmed the statistical dependence between a pos-
itive and negative result of the fluid examination despite
considerable differences in the survival rates between the par-
ticular studies.2,25,30,36–38
5.  Suggested  therapeutic  strategies  for
patients  with  positive  examination  results  of
the peritoneal  washings  for  the  presence  of  free
cancer  cells
At present, there is no standard for treating gastric cancer
patients with a positive result of peritoneal lavage for free
cancer cells. Nevertheless, due to poor prognosis for patients,
attempts have been made to introduce some methods of treat-





Cytoreductive operation HIPEC Yang/2011
d rad438  reports of practical oncology an
therapy after surgical treatment. In the S1 group, a 3-year
survival rate was indeed statistically higher and was 71.6%,
whereas of the patients who underwent only surgery merely
17.1% survived that period of time (p = 0.0002). Yonemura and
co-workers40 obtained similar results in their study. Two years
after surgery. 53% of the patients who received S1 chemother-
apy survived; with no S1 chemotherapy applied, only 9% of the
patients survived the same period of time (p = 0.0002). Unfortu-
nately, the differences in the pharmacokinetics S1 stemming
from different CYP2A6 properties (the enzyme responsible
for S1 metabolism) in the Caucasian population do not allow
to achieve appropriately high concentration of the medica-
tion, which accounts for its low effectiveness in non-Asian
countries.
Shimada and co-workers in a publication of 200241 pointed
out that an intensive lavage of the peritoneal cavity with
physiological saline decreases the CEA level as a marker
of the presence of cancer cells in the peritoneal washing.
The study conclusions were used by Kuramoto and his co-
workers.42 He divided patients in whom the presence of free
cancer cells was detected into three groups: those who were
treated surgically, those treated surgically with a follow-up
of intra-peritoneal chemotherapy and systemic chemother-
apy, and those treated surgically with intensive peritoneal
lavage using ten liters of physiological saline combined with
intra-peritoneal chemotherapy and systemic chemotherapy.
A five-year survival rates of the above groups were 0%, 4.6%
and 43.8% (p < 0.0001), respectively. It is worth noting that in
the group of patients subjected to an intensive peritoneal cav-
ity lavage and who had a good result of 5-year survival, 90%
had a poorly differentiated cancer or a sub-type signet ring
cell (SRC) adenocarcinoma, and in 60% the cancer infiltration
affected the serous membrane of the stomach.
In the second segment of the study, intra-peritoneal
chemotherapy was applied after surgical treatment. 4.6% of
the patients survived 5 years after surgery which is a slightly
better result than that obtain with surgery alone (none of the
patients lived up to 5 years). This indicates that the applica-
tion of this therapeutic method positively affects the survival
rate.
Good results obtained in the treatment of other types of
peritoneum cancer (ovary cancer, colon cancer) support the
notion of applying intra-peritoneal chemotherapy in stom-
ach cancer. Moreover, the application of intra-peritoneal
medicines allows one to obtain a higher degree of concentra-
tion for a longer period of time with fewer undesired effects
in comparison with the systemic application.
The influence of intra-peritoneal chemistry on the results
of the treatment of patients with positive peritoneal cytol-
ogy was also analyzed by Imano and co-workers.43 The study
included ten patients (all of them T3/T4 and 7 from 10 –
N3). Gastrectomy with lymphadenectomy D2 was performed,
then paklitastel was used intra-peritoneally, postoperatively
S1 – a 2-year survival rate was 70%. In the control group who
received only surgical treatment, the 2-year survival rate was
20% (p < 0.01).Another potential therapeutic option is a cytoreductive
treatment with intra-peritoneal chemotherapy in hyperther-
mia  (Hyperthermic Intraperitoneal Chemotherapy (HIPEC)).
Yang and co-workers44 subjected a group of 68 patients withiotherapy 2 2 ( 2 0 1 7 ) 434–440
an IV stage cancer to randomization. The first group was
treated surgically using the HIPEC procedure with cisplatin
and mitomycin C, and the other group was treated with
surgery alone. It transpired that the patients treated with
HIPEC had their survival rate extended to 11 months versus
6.5 months for the other group.
Lorenzen and co-workers,12 in turn, proved that using
systemic chemotherapy prior to radical surgery, based on cis-
paltin, fluorouracil and folic acid in patients with positive
cytology, can converse the status of the cytological liquid to
negative. The change in the cytological state was connected
with lengthening the survival rate to 66.1 months versus 9.2
months for patients in whom no change in cytology was
noticed prior to and after chemotherapy (p = 0.002).
The authors noted that in a group of patients who  had can-
cer progression during neoadjuvant chemotherapy in the form
of conversion from negative to positive cytology of the perit-
oneal cavity liquid, the survival rate was only 18.5 months.
Mezhir and co-workers45 came to similar conclusions while
studying a group of 291 patients with positive peritoneal
cytology. The patients’ cytological status of the peritoneum
liquid was examined during a diagnostic laparoscopy. The
patients with positive result were qualified for neoadju-
vant chemotherapy, whereupon 48 of them again underwent
diagnostic laparoscopy and had their liquid examined. The
neoadjuvant treatment changed the status of the cytological
fluid from positive to negative in 27 patients, while 21 patients
had the same positive result. For the patients who  responded
positively to the treatment, the median time free of relapse
was 2.5 years versus 1.4 years (p = 0.0003) for patients who  did
not respond to the treatment. Out of 27 patients with negative
cytology after treatment, 20 were subjected to radical surgery,
7 were not operated, moreover, survival time was comparable
for the two groups.
The treatment results are promising, but require further
randomized study on large groups of patients, so that the
most effective way of treating patients with positive peritoneal
cytology can be obtained.
6.  Summary
The data presented in medical literature clearly indicate
that in patients with gastric cancer preoperational diag-
nosis should be obligatorily supplemented with diagnostic
laparoscopy combined with tests for the presence of free can-
cer cells. The prognosis for patients who have free cancer cells
in the peritoneum despite the absence of visible peritoneal
dissemination is poor, and employing radical surgery as the
only method must be regarded as palliative treatment.
The therapeutic strategies proposed so far for patients with
positive cytology require further perspective studies leading
to finding an appropriate algorithm which could improve the
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